Enochian Biosciences

$3.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.76%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ENOB and other stocks, options, and ETFs commission-free!

About ENOB

Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA. The listed name for ENOB is Enochian Biosciences, Inc. Common Stock.

CEO
Eric Jean Marie Leire, MD, MBA
Employees
10
Headquarters
Los Angeles, California
Founded
2011
Market Cap
182.49M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
164.25K
High Today
$4.06
Low Today
$3.87
Open Price
$4.01
Volume
208.01K
52 Week High
$13.43
52 Week Low
$1.95

ENOB Earnings

-$0.05
-$0.03
-$0.02
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Mar 16, Pre-Market

You May Also Like

STNG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure